Tzield (teplizumab-mzwv) / MacroGenics, Sanofi, Ligand - LARVOL DELTA

Teplizumab Treatment Induces a Transient Increase in Pancreas Size in Individuals with Type 1 Diabetes (T1D) (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Insulin Initiation during Teplizumab Infusions and Partial Remission after Stage 3 Progression in a Real-World Cohort (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Real-world • Real-world evidence • Metabolic Disorders

Real-World Experiences with Teplizumab: U.S. HCP Perspectives on Infusion Practices (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Real-world • Real-world evidence • Metabolic Disorders

TEPLI-REAL: A Real-World Retrospective Study Characterizing Screening and Treatment Patterns for Type 1 Diabetes (T1D) in Individuals Treated with Teplizumab in the U.S. (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Real-world • Real-world evidence • Retrospective data • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

TEPLI-REAL: A Real-World Retrospective Study Characterizing Individuals with Type 1 Diabetes Treated with Teplizumab and Their Metabolic Outcomes (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Real-world • Real-world evidence • Retrospective data • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Real-world evidence • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Screening for diabetes mellitus type 1 in the pediatric general population: an ethical analysis. (PubMed, Eur J Pediatr) - "What is Known: • Autoantibodies can identify individuals at risk for Type 1 Diabetes before symptom onset, and population screening is increasingly discussed as a strategy to reduce complications such as diabetic ketoacidosis at diagnosis. What is New: • This study provides a structured ethical analysis of general population antibody screening for Type 1 Diabetes using the four-principle framework of Beauchamp and Childress (autonomy, beneficence, nonmaleficence, justice) • It identifies key ethical domains, including decision-making for children, psychological impact, screening timing, resource allocation, and emerging preventive options such as Teplizumab, that should guide future implementation and research on population screening programs."

Journal • Review • CNS Disorders • Diabetes • Metabolic Disorders • Mood Disorders • Pediatrics • Psychiatry • Type 1 Diabetes Mellitus

TREATMENT WITH TEPLIZUMAB IN CHILDREN WITH STAGE 2 TYPE 1 DIABETES: AN ITALIAN CASE SERIES. (ATTD 2026) - "These findings confirm the short-term safety and tolerability of Teplizumab in pediatric stage 2 T1D patients. Follow-up is ongoing to assess long-term efficacy and safety."

Clinical • Diabetes • Hematological Disorders • Immunology • Metabolic Disorders • Pruritus • Thrombocytopenia • Type 1 Diabetes Mellitus

REAL-WORLD USE OF TEPLIZUMAB FOR STAGE 2 TYPE 1 DIABETES: FIRST MULTICENTRE EXPERIENCE IN SPAIN (ATTD 2026) - "This first Spanish multicentre real-world experience indicates teplizumab is feasible and safe in Stage 2 T1D. Ongoing follow-up will assess glycaemic evolution in clinical practice."

Clinical • Real-world • Real-world evidence • Diabetes • Infectious Disease • Leukopenia • Metabolic Disorders • Type 1 Diabetes Mellitus

DEVELOPMENT OF A POINT-OF-CARE TEST FOR THE DETERMINATION OF C-PEPTIDE: AN UPDATE ON WHOLE BLOOD TESTING (ATTD 2026) - "The demand for C-peptide testing is therefore expected to grow rapidly over the next decade as new T1DM treatments, such as the immunotherapy drug teplizumab, become widely available... This study has shown that our novel test device could be used to measure circulating C-peptide rapidly and accurately at the point of care, using small volumes of capillary blood. These findings show clear potential for further testing within a clinical setting."

Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

SCREENING FOR TYPE 1 DIABETES MELLITUS (T1D) IN THE PEDIATRIC POPULATION: DATA FROM A SINGLE-CENTER PROGRAM (ATTD 2026) - "These findings support the benefits of a structured T1D screening program for identifying individuals in preclinical phase, with the goal of delaying disease progression and preventing DKA."

Clinical • Diabetes • Immunology • Metabolic Disorders • Pediatrics • Type 1 Diabetes Mellitus

A-ONE YEAR EXPERIENCE IN SCREENING FOR PRESYMPTOMATIC TYPE 1 DIABETES MELLITUS IN RELATIVES (ATTD 2026) - "All patients in stage 2 have received therapy with Teplizumab. Screening program has detected 2,6% of presymptomatic T1D among relatives, a finding consistent with previously published data. Screening program has detected 2,6% of presymptomatic T1D among relatives, a finding consistent with previously published data. Results support the implementation of screening strategies that enable early interventions to modify disease progression. Expanding the sample size and prospective follow-up will allow optimization of screening strategy."

Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Practicalities of teplizumab infusion (ATTD 2026) - "Supported by Sanofi"

Teplizumab: MOA & clinical insights (ATTD 2026) - "Supported by Sanofi"

Clinical

COULD CGM REPLACE ANTIBODIES SCREENING? (ATTD 2026) - "In addition, new medications that could delay the onset of T1D, e.g., Teplizumab, are also indicated for those who have Stage 2 T1D...The central premise is that CGM cannot replace autoantibody testing for the diagnosis of T1D, but autoantibody testing would be secondary to detection of glucose disturbances and would be used to confirm autoimmune diabetes. In conclusion, given that the initial stages of Genetic risk –> Immune activation are generally undetected for most people who would eventually develop T1D, perhaps a more practical approach to recognition of T1D progression would be the sequence: CGM risk –> differential diagnosis based on ≥ 2 antibodies –> Stage 3 T1D."

Diabetes • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus

IS IT TIME TO RE-EVALUATE OUR RECOMMENDATIONS FOR SCREENING THE GENERAL POPULATION FOR RISK FOR TYPE 1 DIABETES? (ATTD 2026) - "Teplizumab has been the first drug shown to reduce progression from Stage 2 to Stage 3 diabetes (over 50% of patients) and has received FDA approval...The American Diabetes Association recommends screening for Type 1 diabetes in the setting of research studies and in relatives of patients or those with high genetic risk. Wide-scale public health screening in the general population should occur when the cost-benefit equation changes and further interventions are shown to be safe and efficacious in slowing progression of type 1 diabetes."

Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

PARALLEL INDUSTRY 07 (INDUSTRY SESSION NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT): Transforming T1D Management - Practical insights for the use of teplizumab in Stage 2 T1D patients - Industry Symposium Supported by Sanofi (ATTD 2026) - "Supported by Sanofi"

Clinical • CME

Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Sanofi

New trial • Real-world evidence • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

EFC18241: A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diabetes (clinicaltrialsregister.eu) - P2/3 | N=467 | Recruiting | Sponsor: Sanofi-Aventis Recherche & Developpement

New P2/3 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Teplizumab in Stage 2 Type 1 Diabetes: Clinical Practice Experience on Feasibility in 3 Adult Patients. (PubMed, Diabetes Obes Metab) - "Teplizumab administration under compassionate use proved feasible and safe in a real-life academic context, consistent with pivotal trial data. The experience underscores the importance of a structured multidisciplinary approach, integrating endocrinologists, anaesthesiologists, nurses and psychologists to optimise adherence, safety and patient engagement during early disease-modifying immunotherapy in presymptomatic T1D."

Journal • Anesthesia • Diabetes • Immunology • Inflammation • Metabolic Disorders • Mood Disorders • Psychiatry • Type 1 Diabetes Mellitus

Early Detection of Pediatric Type 1 Diabetes: The Expanding Role of Screening. (PubMed, Children (Basel)) - "The review also examines the public health implications, cost-effectiveness, and ethical considerations of implementing population-based screening, particularly in light of emerging disease-modifying therapies such as teplizumab. Overall, available evidence supports screening as a meaningful strategy to shift T1D diagnosis from an acute emergency to a predictable clinical trajectory, with potential benefits extending from individual patient outcomes to healthcare system sustainability."

Journal • Review • Diabetes • Immunology • Metabolic Disorders • Pediatrics • Type 1 Diabetes Mellitus

How to communicate with individuals and caregivers at the time of presymptomatic type 1 diabetes diagnosis. (PubMed, Postgrad Med) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Assessing extracellular vesicle proteins as predictive biomarkers for developing type 1 diabetes. (PubMed, bioRxiv) - "In fact, anti-CD3 antibody (Teplizumab) delays the onset of T1D by 2 years by targeting T cells...In this paper, we assess the potential of plasma extracellular vesicle (EV) proteomics analysis for identifying predictive biomarkers of T1D. Our results show excellent potential of the approach, opening opportunities to perform broader studies to identify biomarkers for developing T1D."

Biomarker • Journal • Diabetes • Immunology • Metabolic Disorders • Type 1 Diabetes Mellitus

Interventional studies targeting the prodromal or preclinical phase of immune-mediated disease to benefit patient outcomes: a scoping review. (PubMed, J Autoimmun) - "Interventions targeting preclinical or prodromal phases of immune-mediated diseases can delay clinical onset, particularly in RA, T1D, and MS. Progress will require harmonized preclinical definitions, improved risk stratification, longer follow-up, and dedicated efforts in underrepresented diseases such as SLE."

Journal • Preclinical • Review • CNS Disorders • Diabetes • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Multiple Sclerosis • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • Type 1 Diabetes Mellitus

TN40A: Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Trial completion date: Dec 2029 ➔ May 2030 | Initiation date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial initiation date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus